Blueprint Medicines Co. (NASDAQ:BPMC) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Blueprint Medicines Co. (NASDAQ:BPMC) have been given an average recommendation of “Moderate Buy” by the twenty ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $123.83.

Several equities analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 price objective on shares of Blueprint Medicines in a research report on Thursday, February 13th. Piper Sandler upped their price objective on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Wedbush reaffirmed an “outperform” rating and issued a $128.00 price objective on shares of Blueprint Medicines in a research report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th.

Insider Buying and Selling

In related news, CEO Kate Haviland sold 1,446 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the sale, the chief executive officer now directly owns 149,378 shares in the company, valued at $16,467,430.72. This represents a 0.96 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jeffrey W. Albers sold 15,161 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the sale, the director now owns 152,396 shares of the company’s stock, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 45,224 shares of company stock worth $4,541,139 in the last three months. 4.21% of the stock is owned by insiders.

Institutional Investors Weigh In On Blueprint Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in Blueprint Medicines in the third quarter valued at about $32,000. R Squared Ltd purchased a new stake in Blueprint Medicines in the fourth quarter valued at about $51,000. Covestor Ltd raised its stake in Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 403 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Blueprint Medicines in the fourth quarter valued at about $65,000. Finally, Thematics Asset Management purchased a new stake in Blueprint Medicines in the fourth quarter valued at about $72,000.

Blueprint Medicines Stock Performance

NASDAQ BPMC opened at $96.57 on Monday. The company has a market cap of $6.17 billion, a P/E ratio of -89.42 and a beta of 0.62. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The business’s 50 day moving average price is $99.54 and its 200-day moving average price is $94.39. Blueprint Medicines has a fifty-two week low of $80.68 and a fifty-two week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Sell-side analysts predict that Blueprint Medicines will post -1.28 earnings per share for the current year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.